Target: ₹276CMP: ₹195.20 Piramal Pharma’s CDMO (Contract Research, Development, and Manufacturing Organisation) arm spans discovery through clinical and commercial supply across ADCs, HPAPIs, peptides, and sterile injectables. We have conducted a deep-dive analysis of its top molecules, peer comparison, and key modalities. The platform’s advantage is scope and proximity, but growth is still sensitive to biotech funding/approval timelines, regulatory outcomes at multi-jurisdiction sites, & utilisation risk i ...